The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial
Abstract
CONTEXT: High platelet reactivity while receiving clopidogrel has been linked to cardiovascular events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue is not well defined. OBJECTIVE: To evaluate the effect of high-dose compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity after PCI. DESIGN, SETTING, AND PATIENTS: Randomized, double-blind, active-control trial (Gauging Responsiveness with A VerifyNow assay-Impact on Thrombosis And Safety [GRAVITAS]) of 2214 patients with high on-treatment reactivity 12 to 24 hours after PCI with drug-eluting stents at 83 centers in North America between July 2008 and April 2010. INTERVENTIONS: High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) or standard-dose clopidogrel (no additional loading dose, 75 mg daily) for 6 months. MAIN OUTCOME MEASURES: The primary end point was the 6-month incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis. The key safety end point was severe or moderate bleeding according to the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) definition. A key pharmacodynamic end point was the rate of persistently high on-treatment reactivity at 30 days. RESULTS: At 6 months, the primary end point had occurred in 25 of 1109 patients (2.3%) receiving high-dose clopidogrel compared with 25 of 1105 patients (2.3%) receiving standard-dose clopidogrel (hazard ratio [HR], 1.01; 95% confidence interval [CI], 0.58-1.76; P = .97). Severe or moderate bleeding was not increased with the high-dose regimen (15 [1.4%] vs 25 [2.3%], HR, 0.59; 95% CI, 0.31-1.11; P = .10). Compared with standard-dose clopidogrel, high-dose clopidogrel provided a 22% (95% CI, 18%-26%) absolute reduction in the rate of high on-treatment reactivity at 30 days (62%; 95% CI, 59%-65% vs 40%; 95% CI, 37%-43%; P < .001). CONCLUSIONS: Among patients with high on-treatment reactivity after PCI with drug-eluting stents, the use of high-dose clopidogrel compared with standard-dose clopidogrel did not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00645918.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309023291001 · Cited by 4,055
Kushner, F. G., Hand, M., Smith, S. C., King, S. B., Anderson, J. L., Antman, E. M., Bailey, S. R., Bates, E. R., Blankenship, J. C., Casey, D. E., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.015 · Cited by 1,911
A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting
Leon, M. B., Baim, D. S., Popma, J. J., Gordon, P. C., Cutlip, D. E., Ho, K. K. L., Giambartolomei, A., Diver, D. J., Lasorda, D. M., Williams, D. O., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812033392303 · Cited by 1,815
Gurbel, P. A., Bliden, K. P., Hiatt, B. L., & O’Connor, C. M. (2003) · Circulation · doi:10.1161/01.cir.0000072771.11429.83 · Cited by 1,544
Shuldiner, A. R. (2009) · JAMA · doi:10.1001/jama.2009.1232 · Cited by 1,505
Bonello, L., Tantry, U. S., Marcucci, R., Blindt, R., Angiolillo, D. J., Becker, R., Bhatt, D. L., Cattaneo, M., Collet, J. P., Cuisset, T., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.047 · Cited by 1,149
Self-citationThe Risk of Determining Risk with Multivariable Models
Concato, J., Feinstein, A. R., & Holford, T. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00009 · Cited by 1,115
Variability in Individual Responsiveness to Clopidogrel
Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Alfonso, F., Macaya, C., Bass, T. A., & Costa, M. A. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.11.044 · Cited by 959
Breet, N. J., van Werkum, J. W., Bouman, H. J., Kelder, J. C., Ruven, H. J. T., Bal, E. T., Deneer, V. H., Harmsze, A. M., van der Heyden, J. A. S., Rensing, B. J. W. M., et al. (2010) · JAMA · doi:10.1001/jama.2010.181 · Cited by 850
Kazui, M., Nishiya, Y., Ishizuka, T., Hagihara, K., Farid, N. A., Okazaki, O., Ikeda, T., & Kurihara, A. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029132 · Cited by 835
Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909475 · Cited by 768
BRANDT, J. T., CLOSE, S. L., ITURRIA, S. J., PAYNE, C. D., FARID, N. A., ERNEST, C. S., LACHNO, D. R., SALAZAR, D., & WINTERS, K. J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02775.x · Cited by 734
Cannon, C. P., Battler, A., Brindis, R. G., Cox, J. L., Ellis, S. G., Every, N. R., Flaherty, J. T., Harrington, R. A., Krumholz, H. M., Simoons, M. L., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01702-8 · Cited by 671
Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis
Buonamici, P., Marcucci, R., Migliorini, A., Gensini, G. F., Santini, A., Paniccia, R., Moschi, G., Gori, A. M., Abbate, R., & Antoniucci, D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.094 · Cited by 656
Price, M. J., Endemann, S., Gollapudi, R. R., Valencia, R., Stinis, C. T., Levisay, J. P., Ernst, A., Sawhney, N. S., Schatz, R. A., & Teirstein, P. S. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn046 · Cited by 651
Self-citationvon Beckerath, N., Taubert, D., Pogatsa-Murray, G., Schömig, E., Kastrati, A., & Schömig, A. (2005) · Circulation · doi:10.1161/circulationaha.105.559088 · Cited by 623
Hochholzer, W., Trenk, D., Bestehorn, H.-P., Fischer, B., Valina, C. M., Ferenc, M., Gick, M., Caputo, A., Büttner, H. J., & Neumann, F.-J. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.065 · Cited by 589
Bertrand, M. E., Legrand, V., Boland, J., Fleck, E., Bonnier, J., Emmanuelson, H., Vrolix, M., Missault, L., Chierchia, S., Casaccia, M., et al. (1998) · Circulation · doi:10.1161/01.cir.98.16.1597 · Cited by 583
Trenk, D., Hochholzer, W., Fromm, M. F., Chialda, L.-E., Pahl, A., Valina, C. M., Stratz, C., Schmiebusch, P., Bestehorn, H.-P., Büttner, H. J., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.056 · Cited by 540
Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Ramírez, C., Sabaté, M., Jimenez-Quevedo, P., Hernández, R., Moreno, R., Escaned, J., Alfonso, F., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2430 · Cited by 538
Jernberg, T., Payne, C. D., Winters, K. J., Darstein, C., Brandt, J. T., Jakubowski, J. A., Naganuma, H., Siegbahn, A., & Wallentin, L. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi877 · Cited by 538
Marcucci, R., Gori, A. M., Paniccia, R., Giusti, B., Valente, S., Giglioli, C., Buonamici, P., Antoniucci, D., Abbate, R., & Gensini, G. F. (2009) · Circulation · doi:10.1161/circulationaha.108.812636 · Cited by 529
Angiolillo, D. J., Shoemaker, S. B., Desai, B., Yuan, H., Charlton, R. K., Bernardo, E., Zenni, M. M., Guzman, L. A., Bass, T. A., & Costa, M. A. (2007) · Circulation · doi:10.1161/circulationaha.106.667741 · Cited by 447
Patti, G., Nusca, A., Mangiacapra, F., Gatto, L., D'Ambrosio, A., & Di Sciascio, G. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.06.038 · Cited by 353
Hochholzer, W., Trenk, D., Fromm, M. F., Valina, C. M., Stratz, C., Bestehorn, H.-P., Büttner, H. J., & Neumann, F.-J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.031 · Cited by 320
Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel
Siller-Matula, J. M., Lang, I., Christ, G., & Jilma, B. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.055 · Cited by 262
Jeong, Y.-H., Lee, S.-W., Choi, B.-R., Kim, I.-S., Seo, M.-K., Kwak, C. H., Hwang, J.-Y., & Park, S.-W. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.025 · Cited by 179
Price, M. J., Nayak, K. R., Barker, C. M., Kandzari, D. E., & Teirstein, P. S. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.01.341 · Cited by 145
Self-citationPrice, M. J., Coleman, J. L., Steinhubl, S. R., Wong, G. B., Cannon, C. P., & Teirstein, P. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.03.054 · Cited by 138
Self-citationBedside Evaluation of Thienopyridine Antiplatelet Therapy
Price, M. J. (2009) · Circulation · doi:10.1161/circulationaha.107.696732 · Cited by 132
Self-citationDurability of platelet inhibition by clopidogrel
Gurbel, P. A., & Bliden, K. P. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00163-2 · Cited by 131
Price, M. J., Berger, P. B., Angiolillo, D. J., Teirstein, P. S., Tanguay, J., Kandzari, D. E., Cannon, C. P., & Topol, E. J. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.02.012 · Cited by 126
Self-citationCampo, G. C., Fileti, L., Cesare, N. D., Meliga, E., Furgieri, A., Russo, F., Colangelo, S., Brugaletta, S., Ferrari, R., & Valgimigli, M. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.103 · Cited by 122
Can We Override Clopidogrel Resistance?
Peña, A., Collet, J., Hulot, J., Silvain, J., Barthélémy, O., Beygui, F., Funck‐Brentano, C., & Montalescot, G. (2009) · Circulation · doi:10.1161/circulationaha.108.857722 · Cited by 121
Migliorini, A., Valenti, R., Marcucci, R., Parodi, G., Giuliani, G., Buonamici, P., Cerisano, G., Carrabba, N., Gensini, G. F., Abbate, R., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.883454 · Cited by 118
Jeong, Y., Kim, I., Park, Y., Kang, M.-K., Koh, J., Hwang, S., Kwak, C. H., & Hwang, J. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.05.007 · Cited by 90
Mangiacapra, F., Barbato, E., Patti, G., Gatto, L., Vizzi, V., Ricottini, E., D’Ambrosio, A., Wijns, W. C., & Sciascio, G. D. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.12.012 · Cited by 59
Barker, C. M., Murray, S., Teirstein, P. S., Kandzari, D. E., Topol, E. J., & Price, M. J. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.07.012 · Cited by 42
Self-citationGenotype-Based Risk and Pharmacogenetic Sampling in Clinical Trials
Schork, N. J., & Topol, E. J. (2010) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400903572779 · Cited by 20
Cited by
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
2014 ESC/EACTS Guidelines on myocardial revascularization
Kolh, P., Windecker, S., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu366 · Cited by 4,199
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Metadata
- Authors
- Price, M. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-03-16
- Volume
- 305
- Issue
- 11
- Pages
- 1097
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2157833432
- Cited by
- 1,308
- References
- 40
- FWCI
- 121.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.